-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on ADC Therapeutics, Raises Price Target to $10

Benzinga·06/13/2025 14:14:19
Listen to the news
Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and raises the price target from $7 to $10.